Hydreight Technologies Announces Corporate Update Highlighting Q3 Momentum, VSDHOne Acceleration, and 2026 Outlook

Executive Summary

• Hydreight Technologies reported Q3 2025 GAAP revenue of $10.52 M (↑132% YoY) and GAAP net income of $362 K, marking a turnaround from a loss in Q3 2024.
• Adjusted EBITDA reached $620 K and cash on hand stood at $18.64 M, underscoring strong liquidity and profitability.
• The company highlighted rapid growth in its multi‑vertical platform (especially VSDHOne), nurse network expansion (+49% YoY sign‑ups), and a 72% YoY increase in pharmacy order volume, positioning it for continued scaling into 2026.

Key Details

• Q3 2025 Financial Highlights
• GAAP revenue: $10.52 M (↑132% YoY)
• Topline revenue (non‑GAAP): $12.83 M (↑110% YoY)
• Gross margin: $2.33 M (up from $1.53 M in Q3 2024)
• Adjusted EBITDA: $620 K
• GAAP net income: $362 K vs. a loss of $90 K in Q3 2024

• Cash on hand at quarter‑end: $18.64 M

• First Nine Months (FY 2025) Metrics

• Topline revenue: $26.71 M (↑61% YoY)
• GAAP revenue: $20.44 M (↑70% YoY)

• Adjusted margin: 28.21%

• Multi‑Vertical Platform – GLP‑1 treatments now represent ~28% of activity; other verticals include TRT, peptides, NAD+, hair loss, genetics, sexual‑health products, ondansetron, and additional categories in development.

• Nurse Network & Clinic Adoption

• 198 new nurse sign‑ups (July–Sept 2025) vs. 133 same period prior year (+49% YoY).

• 593 nurse sign‑ups YTD 2025 vs. 364 YTD 2024 (+63% YoY).

• Pharmacy Volume – Orders up ~72% YoY, reflecting repeat usage and broader category adoption.

• VSDHOne Platform (launched late June 2025)

• Q3 2025 product orders placed: ≈295,000.
• YTD as of Dec 1 2025 total product orders placed: ≈887,000.

• Company on track to meet 2025 target of ~1.3 M product orders placed.

• Strategic Initiatives

• Acquired a 5% stake in Perfect Scripts (option to increase).
• Evaluating profitable multi‑state operators and expanding into genetics, NAD+, oral weight‑management.

• Ongoing growth of partner ecosystem across the U.S.

• Compliance & Infrastructure – Nationwide licensed physicians, state‑by‑state telehealth compliance, integrated 503A/503B pharmacy partners, secure prescribing/fulfillment networks.

• Margin Model & AOV Drivers – Margins vary by treatment category; multi‑vertical adoption improves blended margins; automation and workflow enhancements expected to boost long‑term efficiency.

• 2026 Framework – Focus on margin discipline, increased automation, stronger onboarding processes, expanded multi‑vertical adoption, reinforced compliance and operational infrastructure.

• Guidance – Full 2026 guidance slated for release in mid‑December 2025.

Notable Quotes

“We continue to focus on building Hydreight with a structured and deliberate approach… The recent results and platform activity reflect the infrastructure, partnerships, and operational foundation we have put in place over the past several years.” – Shane Madden, CEO

“Our priorities for 2026—automation, onboarding processes, and multi‑vertical support—are based on ongoing analysis of partner behavior and workflow requirements.” – Shane Madden, CEO